Trend | Range | |
---|---|---|
Favorable risks and loss history | +5% to +7% (for attractive risks, the market may deliver rates close to or at flat) |
While Berkshire Hathaway recently announced they are withdrawing from the medical product liability space in North America effective July 2023, we do not anticipate a ripple effect in the marketplace, and overall capacity is expected to remain stable. That being said, capacity for certain litigated product classes, such as orthopedic implants and proton pump inhibitors continues to tighten.
Following are items of concern for insurers; manufacturers and distributors of drug products might expect to see exclusionary language in the market relating to:
There were significant opioid settlements throughout 2022. The national combined settlement amount from all manufacturers, distributors, pharmacies, etc. is around $54 billion and growing.
Wearable technology, automation and artificial intelligence are among the technological advances continuing to impact the medical device landscape. Underwriters are challenged with shifting their understanding of traditional medical device exposures to incorporate the additional risks presented by these new developments.
According to the FDA, there were 2,160 total medical device recalls in 2022 (168 of these were Class I) and 1,321 total drug recalls (83 of these were Class I). While these numbers were down compared to recent years, product safety and associated recalls remain a major concern for medical product manufacturers. Companies should be exploring stand-alone product recall coverage as a potential addition to their insurance portfolio for reputational and balance sheet protection.
With the demand for pharmaceuticals and medical devices continuing to rise, along with the rapid advances in technology and science, this sector is set to see strong growth well into the future. It is critical to the long-term success of life science companies that they can effectively quantify, mitigate and transfer risk wherever it is appropriate.
Willis Towers Watson hopes you found the general information provided in this publication informative and helpful. The information contained herein is not intended to constitute legal or other professional advice and should not be relied upon in lieu of consultation with your own legal advisors. In the event you would like more information regarding your insurance coverage, please do not hesitate to reach out to us. In North America, Willis Towers Watson offers insurance products through licensed entities, including Willis Towers Watson Northeast, Inc. (in the United States) and Willis Canada Inc. (in Canada).